Treatment of Epilepsy with Myoclonic Atonic Seizures in Patients with a Pathogenic SLC6A1 Gene Variant

Epilepsy with myoclonic atonic seizures (also known as Doose syndrome) presents distinct treatment challenges. When a pathogenic variant in the SLC6A1 gene underlies the condition, this genetic finding defines a specific clinical subgroup with its own evidence base for antiseizure medication selection.

Clinical Scenario

Pathogenic variant in the SLC6A1 gene — a genetically confirmed basis for the epilepsy that directly informs which antiseizure treatments are most appropriate for this patient.

Treatment Approach

Evidence in SLC6A1-related epilepsy points to specific antiseizure medication choices; the full protocol details which agents are supported, in what order, and under what clinical conditions — access below for the complete structured regimen.

Instant Access to Structured Evidence-Based Regimens

References

Valproate has been reported as the most effective drug for SLC6A1-related epilepsies, with lamotrigine and ethosuximide also showing efficacy.

View source ↗